
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA is a clinical-stage biopharmaceutical company specializing in neurodegenerative diseases, with a focus on developing therapeutic and diagnostic products targeting misfolded proteins. The company's promising pipeline includes ACI-7104.056, which has shown a significant 20-fold increase in antibodies against pathogenic variants of aSyn, paving the way for further efficacy assessments. Additionally, the anticipated positive results from the upcoming EVOKE trial for Alzheimer’s disease patients may enhance interest in their NLRP3 program, aligning with the industry's current shift towards safer and more effective treatment strategies.
Bears say
AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, highlighting ongoing financial challenges. The company is exposed to significant risks typical of the biopharmaceutical industry, including potential negative outcomes from clinical trials, regulatory uncertainties, and the pressures of navigating complex and price-sensitive commercial markets. These factors contribute to a negative outlook regarding the company's financial stability and future prospects.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares